Xeljanz (tofacitinib), prescribed to treat moderate to severe rheumatoid arthritis and active psoriatic arthritis in adults, blocks the activity of enzymes that affect immune system function. The drug is also used to treat adults with moderate to severe ulcerative colitis in patients for whom other medications have failed. Safety clinical trials indicated an increased risk of clots in lungs and deaths associated with tofacitinib. In July 2019, the FDA approved a Boxed Warning about increased risk of blood clots and death with higher doses of the medication.
CAMG has thousands of spots and infomercials that can be branded for your firm. Reach out to us for the latest creative offline and online examples*.
*Examples shown are not always current examples.
* These fields are required.
The CAMG Legal Marketing Index®. Significantly increase your marketing success, on us.
CAMG’s Legal Marketing Index® offers unprecedented reporting and comprehensive analysis of real-time data. Because more intelligent marketing decisions mean a better ROI.